Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.26 · Revenue $219.18M · 9 analysts
Est. EPS $-1.03 · Revenue $871.41M · 8 analysts
Est. EPS $-0.30 · Revenue $212.40M · 7 analysts
Est. EPS $-0.23 · Revenue $227.42M · 3 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $1.0B | +28.5% | +34.2% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $22.4M | +111.3% | +131.6% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +89.8% | +5.7% | -0.4% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +5.5% | +126.2% | +138.6% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +2.2% | +108.8% | +123.6% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $45.0M | +151.0% | -336.4% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +4.5% | +139.7% | -225.2% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 131.4% | -36.1% | -12.7% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 3.14x | -26.3% | +15.6% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $1.1B | +21.5% | +0.7% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 0.18 vs 0.26 | -30.9% | 0.15 vs -0.31 | +148.4% |
| Revenue Surprise | $1.0B vs $1.0B | -0.1% | $268.3M vs $208.0M | +29.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| May 14, 2026 | Dunlop A. Sinclair | director | Common Stock | D | 3,544 | — |
| May 14, 2026 | Dunlop A. Sinclair | director | Stock Option (right to buy) | D | 14,684 | $25.12 |
| May 14, 2026 | Dunlop A. Sinclair | director | Stock Option (right to buy) | D | 27,600 | $30.62 |
| May 14, 2026 | Dunlop A. Sinclair | director | Stock Option (right to buy) | D | 11,199 | $31.91 |
| May 14, 2026 | Dunlop A. Sinclair | director | Stock Option (right to buy) | D | 8,554 | $47.28 |
Operator: Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis Pharmaceuticals Fourth Quarter and Full Year 2025 Earnings Conference Call. Please be advised that today's call is being recorded. I will now turn the call over to Eva Stroynowski, Head of Investor Relations. Please go ahead. Eva Stroynowski: Good morning, and thank you for joining us to discuss Apellis' Fourth Quarter and Full Year 2025 financial results. With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois; Executive Vice President of Commercial, David Acheson; Chief Medical Officer, Dr. Caroline Baumal; and Chief Financial Officer, Tim Sullivan. Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail. Now I'll turn the call over to Cedric. Cedric Francois: Thank you, Eva, and thank you all for joining us this morning. Before turning to our fourth quarter results, I'd like to briefly reflect on the progress Apellis made over the course of 2025. It was a year of disciplined execution and foundation building for our company. We strengthened our commercial franchises, advanced key programs across our pipeline and continued to demonstrate the value of our differentiated C3 approach, all while maintaining a strong balance sheet and a clear focus on long-term value creation. These foundations position us well as we move ahead with clear priorities centered on execution, growth and unlocking the next set of value-creating inflection points for Apellis. At our core, Apellis is a company focused on complement biology, specifically targeting C3, the central hub of the complement cascade. By intervening at this central point where all complement pathways converge, we take a fundamentally different approach that enables comprehensive disease control at the root cause while preserving essential immune function. This strategy continues to differentiate us scientifically and commercially and positions us to address a broad range of serious complement-driven diseases. Our 2026 focus remains anchored in our 3 strategic pillars. First, strengthening SYFOVRE's leadership in geographic atrophy. Second, driving growth with EMPAVELI across rare kidney diseases. And third, advancing an innovative pipeline that underpins our next wave of growth. Starting with SYFOVRE. SYFOVRE continues to be a resilient and durable business. In 2025, we delivered steady growth in total injections, and we expect SYFOVRE to remain a stable and meaningful revenue stream through 2026. Last month, co-pay assistance programs at third-party organizations began reopening to new patients. While we do not have visibility into how activity may ramp over time, we are encouraged that …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Cedric Francois | Co-Founder, President, Chief Executive Officer & Director | USD 1,184,788 | — | 1972 | Active |
Caroline R. Baumal | Chief Medical Officer | USD 977,991 | — | 1968 | Active |
Timothy E. Sullivan | Chief Financial Officer & Treasurer | USD 867,358 | Male | 1971 | Active |
David O. Watson | General Counsel & Secretary | USD 851,115 | Male | 1973 | Active |
Pascal Deschatelets | Co-Founder & Chief Scientific Officer | USD 688,055 | — | 1970 | Active |
Nur Nicholson | Chief Technical Operations Officer | USD 373,404 | Female | 1970 | Active |
Kelley Boucher | Chief People Officer | USD 326,383 | Female | — | Active |
Alec Machiels | Co-Founder & Director | USD 92,500 | Male | 1973 | Active |
James G. Chopas | Vice President, Corporate Controller & Chief Accounting Officer | — | Male | 1967 | Active |
Philip Ferrone | Chief Medical Retina Advisor | — | — | — | Active |
Eva Stroynowski | Head of Investor Relations | — | Female | — | Active |
Leslie Meltzer | Chief Research & Development Officer | — | — | — | Active |
David L. Acheson | Executive Vice President of Commercial | — | Male | — | Active |
Mark Jeffrey DeLong | Chief Business & Strategy Officer | — | Male | 1978 | Active |
Peter Hillmen | Head of Hematology Engagement & Member of PNH Scientific Advisory Board | — | — | — | Active |
Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceuticals' research programs as it integrates the rare-disease drugs specialist it purchased for $5.6 billion earlier this year.
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 B
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNAÂ (talazoparib), an oral poly ADP-ri
NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Family Solutions Inc. (NYSE: BFAM) will replace Tri Pointe Homes Inc. (NYSE: TPH). Sumitomo Forestry Group (TSE: 1911) is acquiring Tri Pointe Homes in a deal expected to close soon, pending final closing conditions.
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
